What is the optimal diagnostic and therapeutic approach for a 31‑year‑old man with chronic movement‑sensitive nausea, normal gastroscopy and colonoscopy, current use of domperidone, ondansetron and omeprazole, mild constipation from anti‑emetics, and anxiety about nausea episodes?

Optimal Management of Chronic Movement-Sensitive Nausea with Normal Endoscopy

Immediate Diagnostic Priorities

Your patient requires urgent evaluation for cannabinoid hyperemesis syndrome (CHS) and metabolic causes before escalating pharmacotherapy. 1

Essential Laboratory Work-Up

• Obtain complete blood count, comprehensive metabolic panel (including calcium), thyroid-stimulating hormone, lipase, and urinalysis to exclude metabolic derangements, hypercalcemia, hypothyroidism, and Addison's disease 1
• Urine drug screen is mandatory in this age group to assess for cannabis use, as CHS requires 6 months of cessation for definitive diagnosis 1
• Check serum thiamine before administering any glucose-containing fluids to prevent Wernicke's encephalopathy in the setting of chronic nausea 1
• Monitor electrolytes for hypokalemia, hypochloremia, and metabolic alkalosis from prolonged symptoms 1

Imaging Considerations

• The CT scan already performed is appropriate; avoid repeated endoscopy or imaging unless new symptoms develop 1
• One-time upper GI imaging has been completed with gastroscopy showing only mild gastritis 1

Current Medication Regimen Assessment

Your patient's triple-therapy regimen (domperidone, ondansetron, omeprazole) is appropriate but requires optimization and monitoring. 2, 3

Domperidone Efficacy and Safety

• Domperidone 10 mg three times daily is correctly dosed and has demonstrated 69% symptom improvement in a large cohort of 115 gastroparesis patients, with particular benefit for postprandial fullness, nausea, and vomiting 3
• Continue domperidone as the cornerstone prokinetic agent, as it accelerates gastric emptying (reducing retention from 87.3% to 57.2% at 2 hours) and reduces hospitalizations 4
• Monitor for cardiac side effects (tachycardia/palpitations occurred in 12% requiring discontinuation) and check baseline ECG for QTc prolongation 3, 5
• The current dose of 30 mg/day is within the safe range (studies used 40-120 mg/day) and can be titrated upward if symptoms persist 4

Ondansetron Optimization

• Ondansetron 8 mg up to three times daily is appropriate second-line therapy after 4 weeks of domperidone, targeting different (5-HT3) receptors 2, 1
• Monitor for QTc prolongation, especially given concurrent domperidone use 1
• Ondansetron may worsen constipation—this is the likely culprit for his mild constipation rather than domperidone alone 6
• Consider sublingual formulation if nausea prevents oral absorption 1

Omeprazole Rationale

• Omeprazole 40 mg twice daily is appropriate for the documented mild gastritis and potential acid-related nausea 2
• Continue 30 minutes before meals as currently prescribed 2

Addressing Constipation from Anti-Emetics

The constipation is primarily ondansetron-induced and requires proactive management without discontinuing effective anti-nausea therapy. 2, 6

Laxative Regimen

• Initiate senna 15 mg twice to three times daily as first-line stimulant laxative to increase bowel motility 2
• Do not add docusate (stool softener), as evidence shows senna alone is equally effective 2
• If constipation persists after 3-5 days, add bisacodyl 10-15 mg two to three times daily with a goal of one non-forced bowel movement every 1-2 days 2
• Consider polyethylene glycol (MiraLAX) 17 g daily if stimulant laxatives are insufficient 2
• Encourage fluid intake (at least 1.5 L/day) and gentle physical activity within his mobility limitations 2, 1

Critical Pitfall

• Never discontinue effective anti-emetics to resolve constipation—treat constipation prophylactically and aggressively instead 2

Managing Movement-Sensitive and Anxiety-Related Nausea

The movement sensitivity and anticipatory anxiety require both pharmacologic and non-pharmacologic interventions. 2, 1

Anxiety-Targeted Therapy

• Add lorazepam 0.5-1 mg orally or sublingually 30-60 minutes before triggering events (medical appointments, car travel, stair climbing) for anticipatory nausea 1
• Cognitive behavioral therapy (CBT) is strongly recommended to address conditioned nausea responses and reduce anticipatory anxiety 2, 1
• Consider mirtazapine 7.5-15 mg at bedtime, which provides both anti-nausea effects and anxiolytic properties without extrapyramidal side effects 2

Vestibular Component Management

• The movement sensitivity suggests a vestibular contribution; add meclizine 25 mg three times daily as an antihistamine with vestibular-modulating effects 2, 1
• Alternatively, consider scopolamine 1.5 mg transdermal patch every 3 days for sustained anticholinergic anti-nausea effect 2

Dietary and Lifestyle Modifications

Small, frequent, low-fat meals are essential to prevent overwhelming gastric capacity in functional gastroparesis. 1

• Consume 5-6 small meals daily rather than 3 large meals 1
• Avoid high-fat foods, caffeine (which he has already identified as a trigger), and carbonated beverages 1
• Maintain upright posture for 1-2 hours after meals to facilitate gastric emptying 1
• Continue gentle walking 200-300 meters daily with walking stick assistance to prevent deconditioning while avoiding excessive exertion that triggers nausea 1

Escalation Strategy for Refractory Symptoms

If symptoms persist after 4-8 weeks of optimized therapy, escalate systematically rather than replacing current medications. 2, 1

Third-Line Options (Add, Don't Replace)

• Dexamethasone 4-8 mg twice daily for severe or centrally-mediated nausea, particularly effective when combined with ondansetron 2, 1
• Olanzapine 5-10 mg at bedtime provides broad-spectrum anti-nausea effects through dopamine, serotonin, and histamine receptor blockade 1
• Consider aprepitant 80 mg daily (NK-1 receptor antagonist) if nausea remains the predominant symptom despite other interventions 2

Alternative Prokinetic if Domperidone Fails

• Metoclopramide 10 mg three times daily is the only FDA-approved agent for gastroparesis but carries higher risk of extrapyramidal side effects (especially in young males) 2, 1
• Use metoclopramide only if domperidone proves ineffective after 8-12 weeks at maximum tolerated dose 2

Monitoring and Follow-Up Schedule

Systematic reassessment every 4-6 weeks is essential to adjust therapy and identify treatment failures early. 1

• Review symptom diary (nausea intensity, triggers, meal tolerance, physical activity) at each visit 1
• Repeat ECG at 3 months to monitor QTc interval on dual QT-prolonging agents (domperidone + ondansetron) 1, 3
• Check prolactin level at 6 months if gynecomastia develops (reported in 3/17 patients on chronic domperidone) 4
• Reassess mobility and consider physical therapy referral if deconditioning worsens 1

Critical Pitfalls to Avoid

• Never discontinue domperidone to add metoclopramide—domperidone has superior cardiac safety profile and equal efficacy 5, 7
• Do not use antiemetics if mechanical obstruction is suspected—this can mask progressive ileus and gastric distension 1
• Avoid sequential monotherapy—add agents from different drug classes simultaneously to target multiple receptor pathways 1
• Do not repeat endoscopy unless alarm features develop (weight loss, dysphagia, GI bleeding) 1
• Monitor for extrapyramidal symptoms (akathisia, dystonia) with all dopamine antagonists, particularly in young males 2, 1

Prognosis and Expectations

With optimized multimodal therapy, 60-70% of patients experience significant symptom improvement, though complete resolution is uncommon in functional gastroparesis. 3, 4

• Expect gradual improvement over 2-3 months rather than immediate resolution 3
• Symptom fluctuations are normal and do not indicate treatment failure 4
• Quality of life improvements (88% in domperidone studies) often precede objective symptom score reductions 4
• Long-term maintenance therapy is typically required, with periodic dose adjustments based on symptom patterns 4